about
Intranasal insulin as a treatment for Alzheimer's disease: a review of basic research and clinical evidenceNew drug treatments show neuroprotective effects in Alzheimer's and Parkinson's diseasesLack of the metabotropic glutamate receptor subtype 7 selectively modulates Theta rhythm and working memoryUntargeted metabolomic analysis of human plasma indicates differentially affected polyamine and L-arginine metabolism in mild cognitive impairment subjects converting to Alzheimer's diseaseLack of the metabotropic glutamate receptor subtype 7 selectively impairs short-term working memory but not long-term memoryFirst clinical data of the neuroprotective effects of nasal insulin application in patients with Alzheimer's disease.Blockade of long-term potentiation by beta-amyloid peptides in the CA1 region of the rat hippocampus in vivo.Synaptic plasticity in the hippocampus of a APP/PS1 mouse model of Alzheimer's disease is impaired in old but not young mice.Metabolomic Profiling of Bile Acids in Clinical and Experimental Samples of Alzheimer's DiseaseA novel retro-inverso peptide inhibitor reduces amyloid deposition, oxidation and inflammation and stimulates neurogenesis in the APPswe/PS1ΔE9 mouse model of Alzheimer's disease.Impairments of hippocampal synaptic plasticity induced by aggregated beta-amyloid (25-35) are dependent on stimulation-protocol and genetic background.Chronic treatment with the GLP1 analogue liraglutide increases cell proliferation and differentiation into neurons in an AD mouse model.Liraglutide can reverse memory impairment, synaptic loss and reduce plaque load in aged APP/PS1 mice, a model of Alzheimer's disease.Metabotropic glutamate receptors control gating of spike transmission in the hippocampus area CA1.Abeta42-driven cerebral amyloidosis in transgenic mice reveals early and robust pathology.Neural circuit interactions between the dorsal raphe nucleus and the lateral hypothalamus: an experimental and computational study.Time, space and hippocampal functions.Development of beta-amyloid-induced neurodegeneration in Alzheimer's disease and novel neuroprotective strategies.Wide-ranging alterations in the brain fatty acid complement of subjects with late Alzheimer's disease as detected by GC-MSPharmacological targeting of CSF1R inhibits microglial proliferation and prevents the progression of Alzheimer's-like pathology.Neuroprotective role of (Val(8))GLP-1-Glu-PAL in an in vitro model of Parkinson's disease.Anaesthesia generates neuronal insulin resistance by inducing hypothermiaNew roles for insulin-like hormones in neuronal signalling and protection: new hopes for novel treatments of Alzheimer's disease?Incretin analogues that have been developed to treat type 2 diabetes hold promise as a novel treatment strategy for Alzheimer's disease.The role of GLP-1 in neuronal activity and neurodegeneration.GSK3: a key target for the development of novel treatments for type 2 diabetes mellitus and Alzheimer disease.Potential role of glucagon-like peptide-1 (GLP-1) in neuroprotection.Central effects of GLP-1: new opportunities for treatments of neurodegenerative diseases.New animal models of Alzheimer's disease that display insulin desensitization in the brain.Insulin, incretins and other growth factors as potential novel treatments for Alzheimer's and Parkinson's diseases.Drugs developed for treatment of diabetes show protective effects in Alzheimer's and Parkinson's diseases.Liraglutide improves hippocampal synaptic plasticity associated with increased expression of Mash1 in ob/ob mice.Neuroprotective effects of geniposide on Alzheimer's disease pathology.Neuroprotective effects of glucose-dependent insulinotropic polypeptide in Alzheimer's disease.A Novel Bioresorbable Device as a Controlled Release System for Protecting Cells from Oxidative Stress from Alzheimer's Disease.Novel incretin analogues improve autophagy and protect from mitochondrial stress induced by rotenone in SH-SY5Y cells.Therapeutic Potential of Genipin in Central Neurodegenerative Diseases.Therapeutic potential of flavonoids in spinal cord injury.Neuroprotective and anti-apoptotic effects of liraglutide on SH-SY5Y cells exposed to methylglyoxal stress.Levo-tetrahydropalmatine inhibits the acquisition of ketamine-induced conditioned place preference by regulating the expression of ERK and CREB phosphorylation in rats.
P50
Q24601034-136FA636-998E-4E3D-BFFC-6B5E20323C43Q26866194-5510EEBC-20B0-4FE6-AA8F-A354A6D1E25FQ28513068-49178EE2-08A3-40FC-A808-358087A9C17BQ28544957-DAA4AE94-F51F-4E21-B60C-3C46B2F1D9DAQ28589028-26C678CC-CFFE-4621-A8CA-208A5A770D60Q30757523-B2F736CC-2180-4217-AF02-785AFF2996FEQ31841529-41E3B856-58E4-4F65-ABD1-0C4C2AAA26E2Q33546364-0ED105EE-3FCC-4FD5-8065-6CE119D436A3Q33546364-C04C037A-8580-44FD-B7E0-8F404933BC4DQ33844975-F7181B05-8E2A-488B-8F78-DB24CC0FDD89Q34575658-2FF9188A-BF71-44EF-94B0-C918A336E0F1Q34591360-CC53EE16-48B5-4995-A0CB-4E3C6E1FBB4DQ34639384-E30AAAA5-BF97-4701-BE85-F2A7AB92205BQ34655623-522016AA-2C02-40AB-A2CD-BC5C1B4D58BAQ34738830-786A0977-5523-4745-B351-6C0C60164662Q35016226-4177E2FD-A84C-4E74-BC59-E7D1D2C690D0Q35091506-5D96FC32-9482-4851-BDA0-A107D1614392Q35545443-911748E4-05ED-443A-BC49-9D625BFB2FFAQ36329164-8EDEFB99-910D-4E1F-8105-A791A10CFC5DQ36595126-6F16F07C-EA91-404A-8D4F-1157B28D47B4Q36615483-DD9AEC8D-C996-444E-9428-5347651AEB20Q36737512-D3DE9E84-07CB-4C21-98E0-DDE62CF7C5E2Q36980453-128458DF-2C37-45D3-8E58-9E190D2D72ECQ37302369-665192DF-8715-4113-AAF2-FB5A4FE87C58Q37718840-8B959C9B-A31F-4EC4-8EC5-198A251DC0A2Q37811420-591DC4A4-5CFF-49A5-AEA6-6760462E076BQ38020439-AACBBE7F-6F73-4910-BD7E-023061D13F6AQ38039489-AC03D6CE-58DA-418E-975B-A1D1026B8DE6Q38133759-2CAC5C3E-E4C7-4DBC-B9E9-C53CC6C53D58Q38164626-18692417-B46D-4931-A1AB-7C2F2B6EA795Q38197368-34D43C75-4800-4957-A535-773560059438Q38261606-81CDA606-43E6-4943-8DEF-80201687A89FQ38324750-14A8BA01-8929-4C65-A000-73E156995F17Q38423431-B653D6D8-7522-48AD-B2C2-B7D7411AC607Q38583347-94693B37-7685-46F3-972A-780628B6AFDDQ38739185-814232E6-16D9-4C91-84B0-60E43DF87A70Q38758318-3549634A-456D-41E1-AFBC-9AD94ABBBA04Q38891142-8FAB7A91-5E75-469A-BD88-46678372F195Q39043045-6D026CEE-DCE0-4C5B-9CCC-95D4C04F5434Q39083326-2CBABB25-A8F5-4710-8BC4-57F6248C847E
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Christian Hölscher
@ast
Christian Hölscher
@en
Christian Hölscher
@es
Christian Hölscher
@nl
Christian Hölscher
@sl
type
label
Christian Hölscher
@ast
Christian Hölscher
@en
Christian Hölscher
@es
Christian Hölscher
@nl
Christian Hölscher
@sl
altLabel
Holscher
@en
prefLabel
Christian Hölscher
@ast
Christian Hölscher
@en
Christian Hölscher
@es
Christian Hölscher
@nl
Christian Hölscher
@sl
P106
P1153
55172440800
P21
P31
P4012
P496
0000-0002-8159-3260